Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia.

Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G.

Lung Cancer. 2013 Oct;82(1):171-2. doi: 10.1016/j.lungcan.2013.07.004. Epub 2013 Aug 9.

PMID:
23932362
2.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck S, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HB, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansén S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M.

Cancer Discov. 2011 Jun;1(1):78-89. doi: 10.1158/2159-8274.CD-11-0005.

4.

Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.

Nagao T, Takahashi N, Kameoka Y, Noguchi S, Shinohara Y, Ohyagi H, Kume M, Sawada K.

Intern Med. 2013;52(22):2567-71. Review.

5.

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.

Beauchamp EM, Woods BA, Dulak AM, Tan L, Xu C, Gray NS, Bass AJ, Wong KK, Meyerson M, Hammerman PS.

Mol Cancer Ther. 2014 Feb;13(2):475-82. doi: 10.1158/1535-7163.MCT-13-0817. Epub 2013 Dec 2.

6.

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.

Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB.

Cancer Res. 2014 Dec 15;74(24):7217-28. doi: 10.1158/0008-5472.CAN-14-0505. Epub 2014 Oct 27.

7.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Mar;92(3):401-4.

8.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J.

Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918.

PMID:
19768693
9.

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.

Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A.

Blood. 2009 Dec 3;114(24):4944-53. doi: 10.1182/blood-2009-04-214221. Epub 2009 Sep 24.

10.

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.

Faber E, Mojzikova R, Plachy R, Rozmanova S, Stastny M, Divoka M, Jarosova M, Indrak K, Divoky V.

Leuk Res. 2010 Apr;34(4):e91-3. doi: 10.1016/j.leukres.2009.09.009. Epub 2009 Oct 6. No abstract available.

PMID:
19811824
11.

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.

Cea M, Cirmena G, Garuti A, Rocco I, Palermo C, Cagnetta A, Moran E, Colombo N, Grasso R, Fugazza G, Gobbi M, Nencioni A, Ballestrero A, Patrone F.

Leuk Res. 2010 Sep;34(9):e240-2. doi: 10.1016/j.leukres.2010.03.036. Epub 2010 May 5. No abstract available.

PMID:
20447687
12.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12. No abstract available.

PMID:
21489624
13.

Dasatinib in chronic myelogenous leukemia.

Chu SC, Tang JL, Li CC.

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4. No abstract available.

PMID:
16960978
14.

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.

Hayette S, Chabane K, Michallet M, Michallat E, Cony-Makhoul P, Salesse S, Maguer-Satta V, Magaud JP, Nicolini FE.

Leuk Res. 2011 Jan;35(1):38-43. doi: 10.1016/j.leukres.2010.06.030. Epub 2010 Jul 29.

PMID:
20673586
15.

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.

Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M.

Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12.

16.
17.

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.

Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M.

J Clin Oncol. 2006 Nov 20;24(33):e51-2. No abstract available.

18.

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.

Verma D, Fava C, Kantarjian H, Cortes J.

Am J Hematol. 2009 Apr;84(4):256-7. doi: 10.1002/ajh.21366. No abstract available.

19.

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.

Barańska M, Lewandowski K, Gniot M, Iwoła M, Lewandowska M, Komarnicki M.

J Appl Genet. 2008;49(2):201-3. doi: 10.1007/BF03195613.

PMID:
18436994
20.

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.

Hochhaus A, Kantarjian H.

J Cancer Res Clin Oncol. 2013 Dec;139(12):1971-84. doi: 10.1007/s00432-013-1488-z. Epub 2013 Aug 13. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk